MD Anderson Cancer Center
1515 Holcombe Boulevard
309 articles about MD Anderson Cancer Center
Researchers find protein promotes cancer, suppresses anti-tumor immunity
Researchers at The University of Texas MD Anderson Cancer Center have found that a protein involved in immune response to microbes also can fuel cancer development and suppress immune response to the disease.
1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Cellectis announced that the first patient enrolled in the dose escalation Phase 1 clinical study for its UCART22 product candidate has been dosed at The University of Texas MD Anderson Cancer Center.
Soliton and Emphysys Enter Into a 3-year Development Agreement
Soliton, Inc. announced that it has entered into a Cooperative Development Agreement with Emphysys, an interdisciplinary technology and product development firm just outside Boston, for design and engineering services related to the Company's acoustical shockwave technology.
Prostate cancer bone metastases thwart immunotherapy by producing TGF-β
MD Anderson researchers find abundant cytokine crowds out helper T cells crucial to treatment
NANOBIOTIX Announces New Results From Pre-Clinical Immuno-Oncology Study at SITC 2019
Data presented by MD Anderson demonstrates superiority for NBTXR3 activated by radiation therapy and anti-PD-1 in combination versus the radiation therapy and anti-PD-1 combination in an in vivo anti-PD-1-resistant model
Artios Pharma, MD Anderson and ShangPharma announce in-licensing agreement for DNA damage response inhibitor
Artios Pharma Limited, The University of Texas MD Anderson Cancer Center and ShangPharma Innovation announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.
Under the new deal, Artios Pharma licensed rights to research, develop, manufacture and commercialize products globally from a small-molecule ATR inhibitor program that was jointly developed by MD Anderson and ShangPharma.
Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform
Ongoing Phase 1/2a Study of CD19 CAR-NK with Pivotal Study Expected to Enroll Patients in 2021
They announced an exclusive license deal and research agreement to develop cord-blood derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies.
Soliton's Recent Positive Data Increases Potential Fibrotic Indications
Success in Treatment of Fibrotic Scar Could Lead to Other Indications
Ziopharm said the collaboration with the vaunted cancer research center will use non-viral gene transfer to stably express and clinically evaluate neoantigen-specific T-cell receptors in T cells.
Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program
Accelerates capability for TCR library expansion of T-cell receptors (TCRs) targeting neoatigens, including in hotspots
Cue Biopharma to Present at the Oppenheimer Houston Oncology Summit at the University of Texas MD Anderson Cancer Center
Cue Biopharma, Inc. announced that it will present at the Houston Oncology Summit at the University of Texas MD Anderson Cancer Center on Thursday, October 17, 2019 at 10:40 a.m. CT in Houston, Texas.
Oppenheimer To Host Houston Oncology Summit At The University of Texas MD Anderson Cancer Center
Oppenheimer & Co. Inc. will host its Houston Oncology Summit on October 17, 2019 at the University of Texas MD Anderson Cancer Center.
It was another busy week for clinical trials. Here’s a look.
Soliton Announces Tattoo Technology Article Published in Medical Journal and Selected as Editor's Choice
Article Reviewing Rapid Acoustic Pulse Technology to be included in next "Lasers in Surgery and Medicine" Journal
According to multiple reports, President Donald Trump is set to pick Hahn, a noted radiation oncologist, as the successor to Scott Gottlieb.
Soliton Completes Keloid POC Clinical Trial Treatments
Soliton, Inc. announced it has completed all patient treatments in the keloid scar proof-of-concept trial.
PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients
Phase III trial validates the benefit of veliparib for patients without a BRCA mutation
New clinical data shows that Eli Lilly’s investigational oncology drug pegilodecakin, in combination with a checkpoint inhibitor, could be a potential new treatment for patients with non-small cell lung cancer and kidney cancer.